loading...| Preferred Name |
Cerivastatin |
|
| Synonyms |
|
|
| Definitions |
A synthetic lipid-lowering agent. Cerivastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing major histocompatibility complex II on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. Muscle toxicity (myopathy and rhabdomyolysis) precludes the clinical use of this agent. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C65308 |
|
| CAS_Registry |
145599-86-6 |
|
| CHEBI_ID |
CHEBI:3558 |
|
| Chemical_Formula |
C26H34FNO5 |
|
| code |
C65308 |
|
| Contributing_Source |
FDA |
|
| definition |
A synthetic lipid-lowering agent. Cerivastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing major histocompatibility complex II on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. Muscle toxicity (myopathy and rhabdomyolysis) precludes the clinical use of this agent. |
|
| FDA_UNII_Code |
AM91H2KS67 |
|
| Has_Salt_Form | ||
| in_subset | ||
| label |
Cerivastatin |
|
| Legacy Concept Name |
Cerivastatin |
|
| Preferred_Name |
Cerivastatin |
|
| prefixIRI |
NCIT:C65308 |
|
| prefLabel |
Cerivastatin |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0528023 |
|
| subClassOf |